(Q83698242)

English

Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease

scientific article published on 22 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Tsukasa Nakamura

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Eiichi Sato

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Nobuharu Fujiwara

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Yasuhiro Kawagoe

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Hikaru Koide

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Yoshihiko Ueda

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Masayoshi Takeuchi

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sho-ichi Yamagishi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

22 March 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Clinical Cardiology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

34

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

372-377

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Advanced glycation end products: a Nephrologist's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathophysiology of proteinuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel inhibitors of advanced glycation endproducts

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycosylation: chemistry, biology, and implications for diabetes and aging

2 references

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

https://api.crossref.org/works/10.1002%2FCLC.20885

7 January 2021

based on heuristic

inferred from DOI database lookup

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products and the kidney

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The renal tubulointerstitium in diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advanced glycation end products, oxidative stress and diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs).

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of proteinuria in the progression of chronic renal failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/21432860

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CLC.20885

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432860%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83698242&oldid=1516791824"